Clinical Trials Logo

Clinical Trial Summary

This study will look at how well the new medicine CagriSema helps people with excess body weight losing weight compared to a "dummy" medicine and a medicine called semaglutide. Participants will either get CagriSema, a dummy medicine or semaglutide. Which treatment participants get is decided by chance. Participants will take one injection once a week. The study medicine will be injected briefly with a thin needle, typically in the stomach, thighs or upper arms. The study will last for about 1 year.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05996848
Study type Interventional
Source Novo Nordisk A/S
Contact Novo Nordisk
Phone (+1) 866-867-7178
Email clinicaltrials@novonordisk.com
Status Recruiting
Phase Phase 3
Start date August 15, 2023
Completion date April 8, 2025

See also
  Status Clinical Trial Phase
Completed NCT03629301 - Obesity Treatment Using an Internet-delivered Intervention Based on the Diabetes Prevention Program in Mexican Adults N/A
Completed NCT05607680 - A Study of IBI362 in Participants With Obesity or Overweight Phase 3
Completed NCT05153590 - A Research Study About Weight Loss and Treatment Patterns With the Use of Saxenda® in Adults in Real-life Settings in Switzerland
Recruiting NCT05813925 - A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose Weight Phase 3